References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2020-30-30-36

medalphabet-1801

Research Article

Статьи

Эффективность применения октреотида (Октрайда) для профилактики панкреатита после эндоскопической ретроградной холангиопанкреатографии

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

Крылова

Е. А.

Krylova

E. A.

д. м. н., с. н. с., врач-эндоскопист

г. Днепр

Dnipro

Алейник

Д. В.

Aleinik

D. V.

врач-анестезиолог

г. Днепр

Dnipro

ООО «Он клиник Днепр»УкраинаOn Clinic DniproUkraine

КНП «Клиническая больница скорой медицинской помощи» ДГСУкраинаClinical Emergency HospitalUkraine

2020

22122020

130

Практическая гастроэнтерология (3)

3036

2020

Крылова Е.А., Алейник Д.В.

Krylova E.A., Aleinik D.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/1801

В статье приведены результаты изучения эффективности применения ингибитора секреции панкреатических ферментов октреотида (Октрайда) для профилактики панкреатита после эндоскопической ретроградной холангиопанкреатографии (ЭРХПГ). Показано, что введение Октрайда в дозе 0,3 мг в 500 мл 0,9 %-го NaCl путем непрерывной внутривенной инфузии в течение 7 часов и затем 0,1 мг Октрайда подкожно через 6 и 12 часов после окончания внутривенного вливания значительно снижало частоту панкреатита после ЭРХПГ (4,0 и 22,2 %; р < 0,05) и гиперамилаземии (8,0 и 25,9 %; р < 0,05). Сделан вывод об эффективности Октрайда в профилактике развития панкреатита и гиперамилаземии после ЭРХПГ.

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

эндоскопическая ретроградная холангиопанкреатографияосложненияпост-ЭРХПГ панкреатитпрофилактика

endoscopic retrograde cholangiopancreatographycomplicationspost-ERCP pancreatitisprevention

References1

Иванов Ю. В. Фармако-экономические аспекты использования октреотида в профилактике и комплексном лечении острого послеоперационного панкреатита // РМЖ. 2005. № 26. C. 1781. https://www.rmj.ru/articles/obshchie-stati/Farmakoekonomicheskie_aspekty_ispolyzovaniya_oktreotida_v_profilaktike_i_kompleksnom_lechenii_ostrogo_posleoperacionnogo_pankreatita/

Попова М. А., Леонтьев А. С., Короткевич А. Г., Мерзляков М. В., Шестак И. С. Постманипуляционный панкреатит: актуальность проблемы, сложности диагностики и нерешенные проблемы // Политравма. 2018. № 3. C. 93–101.

Ahmed M, Kanotra R, Savani GT, et al. Utilization trends in inpatient endoscopic retrograde cholangiopancreatography (ERCP): A cross-sectional US experience // Endosc Int Open. 2017. V. 5 (4). E 261–E 271. DOI: 10.1055/s‑0043–102402.

Andriulli A., Leandro G., Federici T. et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis // Gastrointest Endosc. 2007. V. 65. P. 624–632.

Andriulli A., Leandro G., Niro G. et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis // Gastrointest Endosc. 2000. V. 51. P. 1–7.

ASGE Standards of Practice Committee (2017). Adverse events associated with ERCP. Gastrointestinal endoscopy, 85 (1), 32–47. https://doi.org/10.1016/j.gie.2016.06.051

Badalov N, Tenner S, Baillie J. The Prevention, Recognition and Treatment of Post-ERCP Pancreatitis // J Pancreas (Online). 2009. V. 10 (2). P. 88–97.

Bai Y, Ren X, Zhang XF, Lv NH, Guo XG, Wan XJ, Nie ZG, Han ST, Bie P, Tian DA, Ji M, Li ZS. Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial // Endoscopy. 2015. V. 7. Р. 415–420. DOI: 10.1055/s‑0034–1391227.

Banks PA, Bollen TL, Dervenis C, et al; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis‑2012: revision of the Atlanta Classification and definitions by international consensus // Gut. 2013. V. 62 (1). P. 102–111.

Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher T, Pless J. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action // Life Sciences. 1982. V. 31 (11). P. 1133–1140. https://doi.org/10.1016/0024–3205(82)90087-x

Bhatia V., Ahuja V., Acharya S. K., and Garg P. K. A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis // J Clin Gastroenterol. 2011.V. 45. P. 170–176.

Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone // Science. 1973. V. 179 (4068). P. 77–79. https://doi.org/10.1126/science.179.4068.77

Bor R, Madácsy L, Fábián A, Szepes A, Szepes Z. Endoscopic retrograde pancreatography: When should we do it? // World J Gastrointest Endosc. 2015. V. 7 (11). Р. 1023–1031. DOI: 10.4253/wjge.v7.i11.1023.

Buxbaum J, Yan A, Yeh K, et al. Aggressive hydration with lactated Ringer’s solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography // Clin Gastroenterol Hepatol. 2014. V. 12. P. 303–307.

Concepción-Martín M, Gómez-Oliva C, Juanes A, Díez X, Prieto-Alhambra D, Torras X, Sainz S, Villanueva C, Farre A, Guarner-Argente C, Guarner C. Somatostatin for prevention of post-ERCP pancreatitis: a randomized, double-blind trial // Endoscopy. 2014. V. 46. P. 851–856 DOI: 10.1055/s‑0034–1377306.

Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus // Gastrointest Endosc. 1991. V. 37 (3). P. 383–393.

de-Madaria E Statins for the Prevention of Acute Pancreatitis // Am J Gastroenterol. 2017. V. 112 (12). P. 1765–1767.

Dumonceau J. M., Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, et al: Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline – updated June 2014 // Endoscopy. 2014. V. 46. P. 799–815.

Elmunzer B. J., Waljee, A.K., Elta, G.H., Taylor, J.R., Fehmi, S.M., Higgins, P.D. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis // Gut. 2008. V. 57. P. 1262–1267.

Elmunzer BJ. Reducing the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis // Dig Endosc. 2017. V. 29. Р. 749–757. DOI: 10.1111/den.12908.

Feng Y, Navaneethan U, Zhu X, Varadarajulu S, Schwartz I, Hawes R, Hasan M, Yang A Prophylactic rectal indomethacin may be ineffective for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in general patients: A meta-analysis // Dig Endosc. 2017. V. 29 (3). P. 272–280. DOI: 10.1111/den.12779.

Funatsu E, Masuda A, Takenaka M, Nakagawa T, Shiomi H, Yoshinaka H, Kobayashi T, Sakai A et al. History of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Acute Pancreatitis as Risk Factors for Post-ERCP Pancreatitis // Kobe J. Med. Sci. 2017. V. 63 (1). P. E 1–E 8.

Guillemin R. Peptides in the brain: the new endocrinology of the neuron // Science. 1978. P. 390–402. https://doi.org/10.1126/science.212832

Hadi YB, Naqvi SF, Abdelqader A, Kupec J, Nasr J Reduced risk of post ERCP pancreatitis in statin users // BMC Gastroenterol. 2020. 20: 125. Published online 2020 Apr 23. DOI: 10.1186/s12876–020–01264–5.

Hao J. Y., Wu D. F., Wang Y. Z., Gao Y. X., Lang H. P., Zhou W. Z. Prophylactic effect of glyceryl trinitrate on post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized placebo- controlled trial // World J Gastroenterol. 2009. V. 15. P. 366–368.

Hu J, Li P, Zhang T, Chen J, Hu Y, Yu Z, Wang J, Zhu D, Tong X Role of Somatostatin in Preventing Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis: An Update Meta-analysis // Front Pharmacol. 2016. 7: 489. Published online. DOI: 10.3389/fphar.2016.00489.

Katsinelos, P., Kountouras, J., Paroutoglou, G., Beltsis, A., Mimidis, K., Zavos, C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis // Gastrointest Endosc. 2005. V. 62. P. 105–111.

Kubiliun N. M., Adams M. A., Akshintala V. S. et al. Evaluation of pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review // Clin Gastroenterol Hepatol. 2015. V. 13. P. 1231–1239.

Lamberts SWJ, Hofland LJ Anniversary Review: Octreotide, 40 years later // European Journal of Endocrinology. 2019. V. 181 (5). P. R 173–R 183. DOI: https://doi.org/10.1530/EJE‑19–0074

Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebocontrolled, randomized clinical trial // Am J Gastroenterol. 2007. V. 102. P. 46–51. PMID 17266687.

Lyu Y, Cheng Y, Wang B, Xu Y, Du W. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta- analysis of randomized controlled trials // BMC Gastroenterol. 2018. V. 18 (1). 106. DOI: 10.1186/s12876–018–0837–4. 22.

Mahamid M, Watad A, Bragazzi N L., Wengrower D, Wolff J, Livovsky D, Amital H, Adawi M, Goldin E Chronic Use of Statins and Their Effect on Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis // Front Pharmacol. 2018. V. 9: 704. Published online. DOI: 10.3389/fphar.2018.00704.

Manes G., Ardizzone S., Lombardi G., Uomo G., Pieramico O., Porro G. B. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study // Gastrointest Endosc. 2007. V. 65. P. 982–987.

Martinez-Moneo E., Cárdenas-Jaén K., Fernãndez- Laso A. B., Millastre-Bocos J., Torralba Gallego A., Martín Arriero S., et al. Statins chronic use is associated to decreased post-ERCP acute pancreatitis incidence // Pancreatology. 2017. V. 17 (3). P. 77–78. DOI: 10.1016/j.pan.2017.05.244.

Martinez-Torres, H., Rodriguez-lomeli, X., Davalos-cobian, C. et al. Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography // World J Gastroenterol. 2009. V. 15. P. 1600–1606.

Milewski J., Rydzewska G., Degowska M., Kierzkiewicz M., Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis // World J Gastroenterol. 2006. V. 12. P. 3751–3755.

Morales S J., Sampath K, Gardner T B. A Review of Prevention of Post-ERCP Pancreatitis // Gastroenterology & Hepatology. 2018. V. 14 (5). P. 286–292.

Nøjgaard C., Hornum M., Elkjaer M. et al. Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo- controlled multicenter trial // Gastrointest Endosc. 2009. V. 69. P. e31–e37.

Omata F., Deshpande G., Tokuda Y., Takahashi O., Ohde S., Carr-Locke D. L., et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis // J. Gastroenterol. 2010. V. 45. P. 885–895. DOI: 10.1007/s00535–010–0234–4.

Parekh PJ., Majithia R, Sikka SK., Baron TH. The “Scope” of Post-ERCP Pancreatitis // Mayo Clin Proc. V. 92 (3). Р. 434–448. http://dx.doi.org/10.1016/j.mayocp.2016.10.028

Pavel L, Bălan G, Nicorescu A, Gîlcă-Blanariu G, Sfarti C, Chiriac Ş, Diaconescu S, Drug V, Bălan G, Ştefănescu G Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of post-retrograde cholangiopancreatography pancreatitis // World J Clin Cases. 2019. V. 7 (3). P. 300–310. DOI: 10.12998/wjcc.v7.i3.300.

Pekgöz M. Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment // World J Gastroenterol. V. 25 (29). P. 4019–4042. DOI: 10.3748/wjg.v25.i29.4019.

Qin X., Lei W. S., Xing Z. X., Shi F. Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis: an updated meta-analysis // Saudi J. Gastroenterol. 2015. V. 21. P. 372–378. DOI: 10.4103/1319–3767.167187.

Rudin D., Kiss A., Wetz R. V., Sottile V. M. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials // J Gastroenterol Hepatol. 2007. V. 22. P. 977–983.

Seta T, Noguchi Y Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis // Gastrointest Endosc. 2011. V. 73 (4). P. 700–706. DOI: 10.1016/j.gie.2010.09.022.

Sethi S., Sethi N., Wadhwa V., Garud S., Brown A. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis // Pancreas. 2014. V. 43. P. 190–197.

Shaygan-Nejad A, Masjedizadeh AR, Ghavidel A et al. Aggressive hydration with Lactated Ringer’s solution as the prophylactic intervention for postendoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled double-blind clinical trial // J Res Med Sci. 2015. V. 20. P. 838–43.

Shen-Li Z. S. Pan X. Zhang W. J. et al. Effect of octreotide administration in the prophylaxis of post ERCP pancreatitis and hyperamylasemia: a multicenter, placebo controlled, randomized clinical trial // Am J Gastroenterol. 2007. V. 102. P. 46–51.

Testoni P. A., Mariani A., Aabakken L., Arvanitakis M., Bories E., Costamagna G. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline // Endoscopy. 2016. V. 48. Р. 657–683.

Testoni P. A., Bagnolo F., Andriulli A. et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial // Aliment Pharmacol Ther. 2001. V. 15. P. 965–972.

Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post- ERCP pancreatitis // Gastrointest Endosc. 2006. V. 64. P. 726–731.

Vadalà di Prampero S. F., Faleschini G., Panic N., Bulajic M. Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review // Eur. J. Gastroenterol. Hepatol. 2016. V. 28. P. 1415–1424. 10.1097/MEG.0000000000000734.

Wang P., Li Z. S., Liu F., Ren X., Lu N. H., et al. Risk factors for ERCP-related complications: a prospective multicenter study // Am J Gastroenterol. 2009. V. 104. P. 31–40.

Wang ZK, Yang YS, Cai FC, Wang YH, Shi XL, Ding C, Li W. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial // Chin Med J. 2013. V. 126. P. 2403–2408.

Wong L. L., Tsai H. H. Prevention of post-ERCP pancreatitis // World J. Gastrointest. Pathophysiol. 2014. V. 5(1). P. 1–10. DOI: 10.4291/wjgp.v5.i1.1.

Yagci G., Gul H., Simsek A. et al. Beneficial effects of N-acetylcysteine on sodium taurocholate-induced pancreatitis in rats. J Gastroenterol. 2004; 39: 268–276.

Zhang Y., Chen Q. B., Gao Z. Y., Xie W. F. Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses // Aliment Pharmacol Ther. 2009. V. 29. P. 1155–1164.

Zheng M., Chen Y., Bai J., Xin Y., Pan X., Zhao L. Meta- analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis // Pancreas. 2008. V. 37. P. 247–253.

Zouhairi ME, Swartz D, Shah T. Post-ERCP Pancreatitis: Mechanisms, Risk Factors, and Prevention // Pancreatic Dis Ther. 2013. 3: 116. DOI:10.4172/2165–7092.1000116.

The authors declare that there are no conflicts of interest present.